Axsome Therapeutics, Inc. (LON: 0HKF)
London
· Delayed Price · Currency is GBP · Price in USD
101.08
+6.85 (7.27%)
Jan 22, 2025, 7:15 PM BST
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $104.76M USD in the quarter ending September 30, 2024, with 81.27% growth. This brings the company's revenue in the last twelve months to $338.46M, up 51.47% year-over-year. In the year 2023, Axsome Therapeutics had annual revenue of $270.60M with 440.80% growth.
Revenue (ttm)
$338.46M
Revenue Growth
+51.47%
P/S Ratio
n/a
Revenue / Employee
$621.02K
Employees
545
Market Cap
4.02B GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Axsome Therapeutics News
- 23 days ago - Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results - Seeking Alpha
- 23 days ago - Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results - Benzinga
- 23 days ago - Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation - Investor's Business Daily
- 24 days ago - Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 24 days ago - Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 24 days ago - Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study - Reuters
- 24 days ago - Axsome Therapeutics Inc (AXSM) Announces Positive Phase 3 Trial Results for AXS-05 in ... - GuruFocus
- 24 days ago - Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation - GlobeNewsWire